| P50 | author | Frédéric R Santer | Q62594334 |
| | Holger H H Erb | Q83747146 |
| P2093 | author name string | Rhiannon V McNeill | |
| P2860 | cites work | JAK-STAT blockade inhibits tumor initiation and clonogenic recovery of prostate cancer stem-like cells | Q39130848 |
| | Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines | Q39250655 |
| | Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. | Q39329100 |
| | Altered corepressor SMRT expression and recruitment to target genes as a mechanism that change the response to androgens in prostate cancer progression | Q39331871 |
| | Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets | Q39385550 |
| | AR-Q640X, a model to study the effects of constitutively active C-terminally truncated AR variants in prostate cancer cells | Q39390992 |
| | Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy | Q39438635 |
| | Overexpression of androgen receptor enhances the binding of the receptor to the chromatin in prostate cancer | Q39475898 |
| | Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer. | Q39647282 |
| | 5alphaDH-DOC (5alpha-dihydro-deoxycorticosterone) activates androgen receptor in castration-resistant prostate cancer | Q39691064 |
| | Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer | Q39750288 |
| | Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor. | Q39916314 |
| | Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer | Q39954334 |
| | Expression of multidrug resistance genes in normal and cancer stem cells | Q39969949 |
| | Evidence for calpain-mediated androgen receptor cleavage as a mechanism for androgen independence | Q40073673 |
| | Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo | Q40131313 |
| | Overexpression and gene amplification of BAG-1L in hormone-refractory prostate cancer. | Q40132834 |
| | Androgen deprivation increases p300 expression in prostate cancer cells | Q40149224 |
| | Regulation of androgen receptor activity by tyrosine phosphorylation. | Q40219614 |
| | Androgen dependent regulation of protein kinase A subunits in prostate cancer cells | Q40236846 |
| | The androgen receptor co-activator CBP is up-regulated following androgen withdrawal and is highly expressed in advanced prostate cancer | Q40513860 |
| | Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial | Q40885260 |
| | Oxygen free radicals and metallothionein | Q40889930 |
| | Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer | Q41072693 |
| | Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer | Q41354811 |
| | Autologous down-regulation of androgen receptor messenger ribonucleic acid | Q41749647 |
| | Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor | Q22254190 |
| | Src family kinases in tumor progression and metastasis | Q24311656 |
| | Substrate Specificity, Gene Structure, and Tissue-specific Distribution of Multiple Human 3α-Hydroxysteroid Dehydrogenases | Q24324916 |
| | The E3 ubiquitin ligase Siah2 contributes to castration-resistant prostate cancer by regulation of androgen receptor transcriptional activity | Q24337119 |
| | Sequence of the intron/exon junctions of the coding region of the human androgen receptor gene and identification of a point mutation in a family with complete androgen insensitivity | Q24601740 |
| | Development of a second-generation antiandrogen for treatment of advanced prostate cancer | Q24605577 |
| | Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer | Q24616117 |
| | The PSA(-/lo) prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration | Q24625643 |
| | Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer | Q24633279 |
| | Use of prednisone with abiraterone acetate in metastatic castration-resistant prostate cancer | Q26865701 |
| | Beyond T and DHT - novel steroid derivatives capable of wild type androgen receptor activation | Q27007208 |
| | Zinc and zinc transporters in prostate carcinogenesis | Q27010040 |
| | Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. | Q27824849 |
| | A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. | Q27852366 |
| | AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer | Q27853062 |
| | Glioma stem cells promote radioresistance by preferential activation of the DNA damage response | Q27860541 |
| | Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways | Q28212733 |
| | Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells | Q28217019 |
| | Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study | Q28275476 |
| | Backdoor pathway for dihydrotestosterone biosynthesis: implications for normal and abnormal human sex development | Q28277259 |
| | Beyond tumorigenesis: cancer stem cells in metastasis | Q28279788 |
| | Cancer stem cells in solid tumours: accumulating evidence and unresolved questions | Q28293535 |
| | Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells | Q28294874 |
| | Three predominant proteins secreted by the human prostate gland | Q28296600 |
| | The role of protein kinase A pathway and cAMP responsive element-binding protein in androgen receptor-mediated transcription at the prostate-specific antigen locus | Q28305794 |
| | Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer | Q28590839 |
| | Prospective identification of tumorigenic prostate cancer stem cells | Q29547859 |
| | The polycomb group protein EZH2 is involved in progression of prostate cancer | Q29614514 |
| | An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). | Q39127743 |
| | Suppression of metallothionein 3 gene expression by androgen in LNCaP prostate cancer cells | Q41928253 |
| | Proposed morphologic classification of prostate cancer with neuroendocrine differentiation | Q41994427 |
| | Characterization of prostate cancer bone metastases according to expression levels of steroidogenic enzymes and androgen receptor splice variants | Q42054793 |
| | Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer. | Q42153553 |
| | Protein kinase A-mediated phosphorylation of RhoA on serine 188 triggers the rapid induction of a neuroendocrine-like phenotype in prostate cancer epithelial cells | Q42370539 |
| | HDAC inhibitor confers radiosensitivity to prostate stem-like cells | Q42448602 |
| | Prostate stem cell compartments: expression of the cell cycle inhibitor p27Kip1 in normal, hyperplastic, and neoplastic cells. | Q42461063 |
| | SOX2 expression in the developing, adult, as well as, diseased prostate | Q42463444 |
| | Interleukin-6 differentially regulates androgen receptor transactivation via PI3K-Akt, STAT3, and MAPK, three distinct signal pathways in prostate cancer cells | Q43589705 |
| | The anti-apoptotic genes Bcl-X(L) and Bcl-2 are over-expressed and contribute to chemoresistance of non-proliferating leukaemic CD34+ cells | Q44078274 |
| | Monoallelic expression of TMPRSS2/ERG in prostate cancer stem cells | Q44287808 |
| | Receptor protein tyrosine phosphatase alpha signaling is involved in androgen depletion-induced neuroendocrine differentiation of androgen-sensitive LNCaP human prostate cancer cells | Q44615404 |
| | Protein kinase A phosphorylates NCoR to enhance its nuclear translocation and repressive function in human prostate cancer cells. | Q45896408 |
| | Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer | Q46549099 |
| | Mutation of histidine 874 in the androgen receptor ligand-binding domain leads to promiscuous ligand activation and altered p160 coactivator interactions | Q46635702 |
| | Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient | Q46788362 |
| | Advanced prostate cancer--a case for adjuvant differentiation therapy. | Q50920040 |
| | Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells. | Q53347619 |
| | Metallothioneins and resistance to cisplatin and radiation in prostate cancer. | Q53618660 |
| | ANDROGEN RECEPTOR GENE AMPLIFICATION AT PRIMARY PROGRESSION PREDICTS RESPONSE TO COMBINED ANDROGEN BLOCKADE AS SECOND LINE THERAPY FOR ADVANCED PROSTATE CANCER | Q57274821 |
| | MicroRNA Expression Profile of Primary Prostate Cancer Stem Cells as a Source of Biomarkers and Therapeutic Targets | Q58001257 |
| | Is there an antiandrogen withdrawal syndrome with enzalutamide? | Q58813328 |
| | Tumor growth need not be driven by rare cancer stem cells | Q59606871 |
| | Circulating Tumor Cell Analysis in Patients with Progressive Castration-Resistant Prostate Cancer | Q63965940 |
| | Do neuroendocrine cells in human prostate cancer express androgen receptor? | Q63966408 |
| | Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells | Q73202210 |
| | Analysis of PTEN and the 10q23 region in primary prostate carcinomas | Q74531155 |
| | Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer | Q78225972 |
| | Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy | Q79920255 |
| | Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer | Q80352321 |
| | Skewing towards neuroendocrine phenotype in high grade or high stage androgen-responsive primary prostate cancer | Q81917535 |
| | The mutational landscape of lethal castration-resistant prostate cancer | Q29614634 |
| | Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma | Q29615607 |
| | Increased survival with enzalutamide in prostate cancer after chemotherapy | Q29617511 |
| | Androgen induces a switch from cytoplasmic retention to nuclear import of the androgen receptor | Q30412857 |
| | Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer | Q30485336 |
| | Modeling the prostate stem cell niche: an evaluation of stem cell survival and expansion in vitro | Q30503574 |
| | AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression | Q30513836 |
| | TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer. | Q30554439 |
| | Neuroendocrine differentiation of human prostatic primary epithelial cells in vitro | Q30850776 |
| | Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer | Q33235187 |
| | Characterization of benign and malignant prostate epithelial Hoechst 33342 side populations | Q33291181 |
| | Role of androgens and the androgen receptor in epithelial-mesenchymal transition and invasion of prostate cancer cells | Q33694557 |
| | The Activity of SN33638, an Inhibitor of AKR1C3, on Testosterone and 17β-Estradiol Production and Function in Castration-Resistant Prostate Cancer and ER-Positive Breast Cancer | Q33770742 |
| | T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer | Q33952036 |
| | Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer | Q34204078 |
| | Studies on Prostatic Cancer: I. The Effect of Castration, Of Estrogen and of Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the Prostate | Q34215208 |
| | Androgen Receptor Gene Amplification and Protein Expression in Recurrent Prostate Cancer | Q34268323 |
| | Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade | Q34390313 |
| | Stem cell differentiation within the human prostate epithelium: implications for prostate carcinogenesis | Q34394076 |
| | Enzalutamide in metastatic prostate cancer before chemotherapy | Q34422206 |
| | Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer | Q34461177 |
| | Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cells | Q34487820 |
| | Domains of the Human Androgen Receptor Involved in Steroid Binding, Transcriptional Activation, and Subcellular Localization | Q34671706 |
| | Constitutively active androgen receptor variants upregulate expression of mesenchymal markers in prostate cancer cells | Q34713218 |
| | Androgen receptor splice variants contribute to prostate cancer aggressiveness through induction of EMT and expression of stem cell marker genes | Q34734595 |
| | Constitutively active AR-V7 plays an essential role in the development and progression of castration-resistant prostate cancer | Q34883636 |
| | Androgen modulation of coregulator expression in prostate cancer cells. | Q34928162 |
| | A three-marker FISH panel detects more genetic aberrations of AR, PTEN and TMPRSS2/ERG in castration-resistant or metastatic prostate cancers than in primary prostate tumors | Q35009891 |
| | Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth | Q35168294 |
| | Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors | Q35178389 |
| | Destruction of full-length androgen receptor by wild-type SPOP, but not prostate-cancer-associated mutants | Q35181646 |
| | Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants | Q35249697 |
| | TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate | Q35256427 |
| | Polycomb-mediated silencing in neuroendocrine prostate cancer. | Q35336915 |
| | PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate. | Q35540013 |
| | Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. | Q35575633 |
| | Mechanistic rationale for MCL1 inhibition during androgen deprivation therapy | Q35742477 |
| | Differential targeting of androgen and glucocorticoid receptors induces ER stress and apoptosis in prostate cancer cells: a novel therapeutic modality | Q35974731 |
| | Androgen receptor splice variants activate androgen receptor target genes and support aberrant prostate cancer cell growth independent of canonical androgen receptor nuclear localization signal | Q36003940 |
| | Mechanisms of the androgen receptor splicing in prostate cancer cells | Q36005683 |
| | Notch signaling modulates hypoxia-induced neuroendocrine differentiation of human prostate cancer cells | Q36206248 |
| | Activation of the glucocorticoid receptor is associated with poor prognosis in estrogen receptor-negative breast cancer | Q36445441 |
| | Opposing effects of androgen deprivation and targeted therapy on prostate cancer prevention | Q36536821 |
| | p63 in prostate biology and pathology | Q36945766 |
| | Prostate stem cells and benign prostatic hyperplasia | Q37127502 |
| | ERG/AKR1C3/AR Constitutes a Feed-Forward Loop for AR Signaling in Prostate Cancer Cells | Q37157965 |
| | Metastatic castration-resistant prostate cancer reveals intrapatient similarity and interpatient heterogeneity of therapeutic kinase targets | Q37377562 |
| | Prostate cancer originating in basal cells progresses to adenocarcinoma propagated by luminal-like cells | Q37394982 |
| | A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer | Q37596247 |
| | Focal amplification of the androgen receptor gene in hormone-naive human prostate cancer. | Q37650612 |
| | Coregulator control of androgen receptor action by a novel nuclear receptor-binding motif | Q37691685 |
| | Roles of cAMP and cAMP-dependent protein kinase in the progression of prostate cancer: Cross-talk with the androgen receptor | Q37784867 |
| | Insulin-like growth factor pathway: a link between androgen deprivation therapy (ADT), insulin resistance, and disease progression in patients with prostate cancer? | Q37887276 |
| | Prostate cancer stem cells: are they androgen-responsive? | Q37908503 |
| | Androgen receptor co-activators in the regulation of cellular events in prostate cancer. | Q37959244 |
| | EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. | Q38169849 |
| | Androgen-deprivation therapy-induced aggressive prostate cancer with neuroendocrine differentiation | Q38192816 |
| | Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies | Q38208748 |
| | Inappropriate activation of the androgen receptor by nonsteroids: involvement of the Src kinase pathway and its therapeutic implications | Q38307975 |
| | Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. | Q38349829 |
| | Are androgen receptor variants a substitute for the full-length receptor? | Q38350089 |
| | Human ASH-1 promotes neuroendocrine differentiation in androgen deprivation conditions and interferes with androgen responsiveness in prostate cancer cells. | Q38421322 |
| | Selective expression of CD44, a putative prostate cancer stem cell marker, in neuroendocrine tumor cells of human prostate cancer | Q38422951 |
| | The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors | Q38964546 |
| | A hormone-dependent feedback-loop controls androgen receptor levels by limiting MID1, a novel translation enhancer and promoter of oncogenic signaling | Q38986420 |
| | The role of high cell density in the promotion of neuroendocrine transdifferentiation of prostate cancer cells. | Q38989505 |
| | Interleukin-6 induces neuroendocrine differentiation (NED) through suppression of RE-1 silencing transcription factor (REST). | Q38995864 |
| | High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development | Q39041750 |
| | The Fer tyrosine kinase acts as a downstream interleukin-6 effector of androgen receptor activation in prostate cancer | Q39117016 |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 133-144 | |
| P577 | publication date | 2015-08-21 | |
| P1433 | published in | Seminars in Cancer Biology | Q1908668 |
| P1476 | title | Therapy escape mechanisms in the malignant prostate | |
| P478 | volume | 35 | |